IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
24.63
-0.30 (-1.20%)
At close: Sep 12, 2025, 4:00 PM EDT
24.54
-0.09 (-0.35%)
After-hours: Sep 12, 2025, 5:45 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $7.00M in the twelve months ending June 30, 2025, down -41.48% year-over-year. In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%.
Revenue (ttm)
$7.00M
Revenue Growth
-41.48%
P/S Ratio
308.13
Revenue / Employee
$53,435
Employees
131
Market Cap
2.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IDYA News
- 5 days ago - IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript) - Seeking Alpha
- 5 days ago - IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst - Seeking Alpha
- 5 days ago - IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer - PRNewsWire
- 5 days ago - IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma - PRNewsWire
- 6 days ago - IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer - PRNewsWire
- 9 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - PRNewsWire
- 10 days ago - IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 10 days ago - IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors - PRNewsWire